Advertisement

Topics

Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017

18:20 EST 1 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
First report of data evaluating investigational selective IDO1 inhibitor alone and in combination with Opdivo Initial presentation of overall survival data from Phase 3 CheckMate -067 assessing Opdivo monotherapy or in ...

Other Sources for this Article

Bristol-Myers Squibb
Media:
Audrey Abernathy, cell: 919-605-4521
audrey.abernathy@bms.com
or
Sarah Koenig, 609-252-4145, cell: 908-397-5379
sarah.koenig@bms.com
or
Investors:
Bill Szablewski, 609-252-5894
william.szablewski@bms.com
or
Tim Power, 609-252-7509
timothy.power@bms.com

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...